If this is true you can kiss shareholder returns goodbye. In my past biotech investments the institution / college usually receives 2 to 5% of revenues, although most failed and no money was ever transferred. But it might explain why disciples here and management avoid the subject like the plague. And why everything is so loosey-goosey with UCLA. It had better not be true.
UCLA's effective share of net royalties is thus ~65% (15% research + 50% of the general pool, adjusted for system-wide allocation). This applies to all inventions, including drugs,